OasisLMS

Learner Objectives
Upon completion of this activity, you should be able to:

1. Identify symptomology of cardiac amyloidosis including key clinical characteristics.
2. Select appropriate testing and recognize findings suggestive of amyloidosis including biomarkers and echo.
3. Review treatment options for patients diagnosed with cardiac amyloidosis.
4. Identify the role and responsibilities of the multidisciplinary and interprofessional care team.

Faculty
Amrut Ambardekar, MD, FACC
University of Colorado Health
Disclosure
Nothing to disclose.

Richard Kar-Hang Cheng, MD, FACC
University of Washington Medical Center
Disclosure
Nothing to disclose.

Jan Griffin, MD, FACC
Medical University of South Carolina
Disclosure 
Fees/Honoraria: AstraZeneca Pharmaceuticals, Bridgebio, Pfizer Inc
Research/Research Grants: Pfizer
Other: Bridgebio, Scripps

Planning Committee
Michelle Maya Kittleson, MD, FACC (Chair)
California Heart Center
Disclosure
Nothing to disclose.

Target Audience
This course is intended for general cardiologists and other members of the CV team who see patients with amyloid or possible amyloid.

Important Dates 
Date of Release: June 30, 2025
Term of Approval/Date of Expiration: June 30, 2026

Grant Acknowledgement
Educational grant support for this activity provided by: Alnylam Pharmaceuticals Inc., BridgeBio Pharma Inc., and Pfizer